Aβ and Aδ fibers, 13, 33
action potential, of nociceptive signal, 19
activity-dependent nociception, in pain
pathways, 19
acupuncture, 120
acute pain: and analgesic effects from
opiates, 83; definition of, 20;
difference between chronic pain and,
21; and nociceptive pain, 22–23
adjuvants, and drugs, 119
aerobic exercise, 129
affective spectrum disorder, and
fibromyalgia, 62–63
allodynia, 26, 33, 48
alpha 1 adrenergic receptor blockade,
88
alpha 2 delta ligands, 90–95. See also
gabapentin; pregabalin
alternative treatments, and drugs, 120
American College of Rheumatology
(ACR), 58–59
amitriptyline, 89
amoxapine, 89
amphetamines, 119
amygdala, 18, 60. See also brain
algesia, and effects of opiates, 83
anandamide (endogenous cannabinoid),
44
anticonvulsants: actions of, 107; off-label
use of for neuropathic pain, 118;
overview of, 106. See also
carbamazepine; gabapentin;
lamotrigine; oxcarbazepine;
phenytoin; pregabalin; topiramate;
zonisamide
antidepressants, 54–55, 73. See also
cyclic antidepressants
antihistamines, 119
anti-nuclear antibody (ANA), 52
anxiety disorders: and fibromyalgia, 61,
63, 66; limbic pathway and emotional
component of pain, 18; pain as
symptom of, 77–78; and pregabalin,
94; and temporomandibular joint
disorder, 75. See also generalized
anxiety disorder
back pain: and changes in brain
structure, 40, 42, 43; and chronic
low-back pain as pain disorder, 72;
cost of healthcare for, 7; and fibrofog,
42; and topiramate, 114; and tricyclic
antidepressants, 87
baclofen, 74, 118
balneotherapy, 129
biofeedback, 129
bipolar disorder, and fibromyalgia, 66
botulinum toxin, 120
bradykinin (BK) and bradykinin 2 (B2)
receptors, 15
brain, chronic pain and changes in, 40–43. See also amygdala; dorsolateral prefrontal cortex; neurobiology; periaqueductal gray brainstem, 17

caffeine, 119
cannabinoids and cannabis, 44, 119
capsaicin, 73, 120
carbamazepine, 74, 108–109
caretakers, and impact of pain, 5
central nervous system, and diagnosis of pain disorders, 57. See also central sensitization
central pain, clinical differences between peripheral pain and, 24
central sensitization: and alpha 2 delta ligands, 90, 91; and anticonvulsants, 107; and excessive nociceptive activity, 31; and fibromyalgia, 58; and increase in painful symptoms, 34–36. See also central nervous system C-fibers, 13, 33
chondroitin sulfate, 120
chronic low-back pain. See back pain
chronic pain: association of with psychiatric disorders, 24; and central sensitization, 34; and changes in brain, 40–43; communication and treatment of, 130; definition of, 20; difference between acute pain and, 21; non-pharmaceutical adjunct treatments for, 129; opiates for maintenance treatment of, 84; and posttraumatic stress disorder in veterans, 79
chronic pelvic pain, 76
chronic widespread pain, and fibromyalgia, 68
cognitive behavioral therapy (CBT), 129
cognitive function: and duloxetine, 98; and fibromyalgia, 65; and reduction of gray matter in chronic pain, 42. See also fibrofog communication, and treatment of chronic pain, 130
complete blood count with differential (CBC), 52
complex regional pain syndrome (CRPS), 70
cost, of pain to healthcare system, 7
C-reactive protein (CRP), 52
Cyclooxygenase-inhibiting nitric oxide donating drugs (CINODs), 86
cyclooxygenase (COX)-2 inhibitors, 86
CYP450 2D6 inhibitor, 102
daily living activities, impact of pain on, 4, 69
deep sleep, 64
dependence, and long term effects of opiates, 84
depression: prevalence of pain comorbid with, 4; and temporomandibular joint disorder, 75. See also major depressive disorder
desipramine, 89
desvenlafaxine, 104–105
diabetic peripheral neuropathic pain (DPNP), 69, 98, 114
diabolical learning models, 38–39
diagnosis, of fibromyalgia, 58–59. See also patients
directed history, 50
disability, and impact of chronic or recurrent pain, 2, 4, 5, 6, 9. See also impairments
discriminatory pathway, 17
dorsal horn: and nociception, 15–17; and segmental central sensitization, 35
dorsal root ganglion, 13
dorsolateral prefrontal cortex (DLPFC), and fibromyalgia, 65
doxepin, 89
drugs: and adjuvants, 119; and alternative treatments, 120; and communication with patient, 130; and complex regional pain syndrome, 70; efficacy of various and hypotheses on
neurologic basis of neuropathic pain, 45; and off-label neuropathic agents, 118; overview of, 81. See also alpha 2 delta ligands; anticonvulsants; antidepressants; lidocaine; non-steroidal anti-inflammatory drugs; norepinephrine reuptake inhibitors; opiates; serotonin norepinephrine reuptake inhibitors; side effects
drug mechanism hypotheses, for neurobiologic basis of neuropathic pain, 45
duloxetine, 71, 98–99
eccentric activity, and peripheral sensitization, 32–33
education, and treatment of chronic pain, 129
electrolyte panel, 52
emotional/motivational pathway, 17–18
endocannabinoid deficiency hypothesis, 44
ephaptic cross-talk, and peripheral sensitization, 33
epidemiology. See prevalence erythrocyte sedimentation rate (ESR), 52
eslicarbazepine, 110
excessive nociceptive activity, and central sensitization, 31
family, and impact of pain, 5
fatigue, and fibromyalgia, 60
fibrofog, 60, 65
fibromyalgia: as affective spectrum disorder, 62–63; and alpha 2 delta ligands, 94, 96; and cannabinoids, 44; and changes in brain, 40, 43; as cognitive disorder, 65; comorbidity with mood and anxiety disorders, 18, 61, 63, 66; and descriptive terms for pain, 48; diagnosis of, 58–59; and duloxetine, 98; etiology of, 61; impairment and symptoms of, 60; and milnacipran, 100; and serotonin
norepinephrine reuptake inhibitors, 96; as sleep disorder, 64
gabapentin, 74, 90, 92–93
gender, and diagnosis of fibromyalgia, 59, 67–68
generalized anxiety disorder: and duloxetine, 98; and fibromyalgia, 62. See also anxiety disorders
glucosamine, 120
gray matter, and chronic pain, 41–43. See also periaqueductal gray
headaches: and cannabinoids, 44; and changes in brain structure, 40; and trigeminal neuralgia, 74. See also migraines
herpes zoster virus, 73
histamine 1 (H1) receptor, 15, 88
hyperalgesia: and cannabinoids, 44; definition of, 25; and ephaptic cross-talk in peripheral sensitization, 33; and inflammatory pain, 28
hypnotherapy, 129
hypothalamus, 60
impairments, and symptoms of fibromyalgia, 60. See also disability inflammatory pain, and hyperalgesia, 28
integrated care system, 128
irritable bowel syndrome, 40, 43, 44
ketamine, 121
laboratory tests, 52
lamotrigine, 74, 112–13
learning, and “un-learning” of pain, 38–39
legal issues, in pain treatment, 124
levetiracetam, 118
licarbazepine, 110
lidocaine, 14, 73, 85, 121
lifestyle, impact of pain on, 1, 4. See also daily living activities
**limbic pathways, 17–18**

<table>
<thead>
<tr>
<th><strong>locus coeruleus, 29</strong></th>
</tr>
</thead>
</table>

**major depressive disorder: and desvenlafaxine, 104; and duloxetine, 98; and fibromyalgia, 62, 66; pain as symptom of, 78. See also depression medical care: and cost of pain, 7; pain as reason for seeking, 3; and physical examination of patient, 51. See also laboratory tests; treatment meditation, as alternative treatment, 120 methadone, 121 migraines, 43, 114. See also headaches milnacipran, 100–101 mixed pain, compared to central and peripheral pain, 24 mood disorders: and fibromyalgia, 18, 63, 66; limbic pathway and emotional component of pain, 61; pain as symptom of, 77–78. See also depression multiple sclerosis (MS), 74 muscarinic M1 and M3 receptor blockade, 88 natural products, and alternative treatments, 120 nerve fibers, and nociception, 13 neurobiology, of pain: and allodynia, 26; and drug mechanism hypotheses, 45; and endocannabinoid deficiency hypothesis, 44; and gray matter hypothesis, 41–43; and hyperalgesia, 25, 28; and inflammatory pain, 28; and neuropathic pain, 27, 29–30; and noncompliance, 12–17, 19, 22–23, 31; overview of, 11; and peripheral sensitization, 32–33 neuropathic pain: and “abnormal” pain, 29–30; definition of, 27; difference between acute pain and, 22; and drug mechanism hypotheses, 45; and duloxetine, 98; risk factors for, 51. See also diabetic peripheral neuropathic pain neurotransmitters, and nociception, 16–17, 19 NMDA-blockers, 121 nociception: activity-dependent in pain pathways, 19; definition of, 12; and excessive activity, 31; and nerve fibers, 13; and “normal” pain, 22–23; and perception, 17; and segmental central sensitization, 35; and transduction, 14–15; and transmission, 16 non-compliance, of patient with treatment, 124 non-steroidal anti-inflammatory drugs (NSAIDs), 86 norepinephrine: chronic pain and deficient, 29; and serotonin norepinephrine reuptake inhibitors, 97; and tricyclic antidepressants, 87. See also norepinephrine transporter norepinephrine reuptake inhibitors (NRIs), and back pain, 72 norepinephrine transporter (NET), 100, 102, 104 nucleus accumbens, and fibromyalgia, 60 obsessive-compulsive disorder, and fibromyalgia, 66 older patients, prevalence of pain in, 2 opiates: analgesic effects from, 83; long term effects of use, 84; pain patients and “opiate problem,” 53–55 osteoarthritis, 71, 87 oxcarbazepine, 74, 110–11 pain: consequences of inadequate treatment for, 8; impact and cost of, 1, 4–7; learning and “unlearning” of, 38–39; patient perception of, 3, 127; prevalence of, 1, 2; risk factors for disability from, 9. See also acute pain; chronic pain; cognitive function; drugs; neurobiology; neuropathic pain; pain disorders; patients; symptoms; treatment |
pain disorders: overview of, 57; preemptive treatment of, 37; treatment of as chronic disease, 128. See also back pain; chronic pelvic pain; complex regional pain syndrome; diabetic peripheral neuropathic pain; fibromyalgia; osteoarthritis; temporomandibular joint disorder; trigeminal neuralgia panic disorder, and fibromyalgia, 66 parabrachial nucleus, 18 patients: and directed history, 50; and laboratory tests, 52; and non-compliance, 124; and “opiate problem,” 53–55; overview of, 47; perception of and perspective on pain by, 3, 17, 127; and physical examination, 51; and presentation of pain, 48; and ruling out of other diagnoses, 49. See also treatment pelvic pain, 76 perception, of pain, 3, 17 periaqueductal gray: and cannabinoids, 44; chronic pain and changes in, 41; and nociception, 17, 18. See also gray matter peripheral nervous system, and pain disorders, 57. See also peripheral sensitization peripheral pain, clinical differences between central pain and, 24. See also diabetic peripheral neuropathic pain peripheral sensitization: and anticonvulsants, 107; and ectopic activity, 32; and ephaptic cross-talk, 33. See also peripheral nervous system personal relationships, impact of pain on, 4 phantom pain, 40 phenytoin, 74, 118 physical examination, 51 polypharmacy, and complex regional pain syndrome, 70 postherpetic neuralgia (PHN), 57 postherpetic neuropathic pain (PHN), 73 posttraumatic stress disorder (PTSD): and fibromyalgia, 66, 68; pain as symptom of, 79; and temporomandibular joint disorder, 75 precipitant contributory factors, for disability from pain, 9 preemptive treatment, of pain disorders, 37 pregabalin, 74, 90, 94–95 premorbid risks, for disability from pain, 9 presymptomatic treatment, 37 prevalence: of comorbidity of fibromyalgia with mood and anxiety disorders, 66; of pain, 1, 2; of pain comorbid with depression, 4; of pain as symptom of anxiety and mood disorders, 78 primary afferent neurons, 13, 14 prodomal treatment, and stress sensitization, 37 psychiatric disorders, and chronic neuropathic pain, 24. See also anxiety disorders; bipolar disorder; depression; mood disorders; obsessive-compulsive disorder; panic disorder; posttraumatic stress disorder rapid eye movement (REM) sleep disorder, 64 rating scales, 125–26 reward circuits, and action of opiates, 84 risk factors: for back pain, 72; for disability from pain, 9; for neuropathic pain disorder, 51 S-adenosylmethionine, 120 Schwann cells, 32 segmental central sensitization, 34–35 serotonin: and neuropathic pain, 30; and serotonin norepinephrine reuptake inhibitors, 97; and tricyclic antidepressants, 87. See also serotonin transporter serotonin norepinephrine reuptake inhibitors (SNRIs), 96–105
transduction, and nociception, 14–15
treatment, of pain and pain disorders:
and communication, 130; of complex
regional pain syndrome, 70;
consequences of inadequate, 8; and
integrated care system, 128; legal
issues in, 124; non-pharmacological
adjunct forms of for chronic pain, 129;
overview of, 123; stress sensitization
and preemptive, 37; and
under-treatment, 8, 124. See also
drugs; patients
tricyclic antidepressants, 87–89
trigeminal neuralgia, 48, 74, 108
triptans, 120
tubero-mammillary nucleus, 65
vanillinoid 1 (VR1) receptor, 15
venlafaxine, 102–103
veterans, and comorbidity of
posttraumatic stress disorder and
chronic pain, 79
voltage-sensitive calcium channels
(VSCCs): and alpha 2 delta ligands,
90, 91; and anticonvulsants, 107; and
nociception, 15
voltage-sensitive ion channel
depolarization, 14, 19
voltage-sensitive sodium channels
(VSSCs): and anticonvulsants, 107;
and nociception, 14–15; and
peripheral sensitization, 32; and
tricyclic antidepressants, 88
voxel-based morphometry (VBM), 41

wind-up, and segmental central
sensitization, 35
withdrawal, from venlafaxine, 102
women, and fibromyalgia, 67
work and workplace, and impact of
pain, 4, 6

XP-13512, 92

zonisamide, 116–17